This month gives those of us with chronic Lyme disease something to really celebrate.

If you have been following along with the developments at Viral Genetics, you will be interested to know that Dr.Luc Montagnier, co-winner of the 2008 Nobel Prize for Medicine and the co-discoverer of the HIV virus, has joined Viral Genetics as a research consultant.  He is the co-founder of the World Foundation for AIDS Research and Prevention and co-directs the Program for International Viral Collaboration.

Dr. Montagnier, was quoted as saying, “While some preventive candidate vaccines failed to protect against HIV infection, and since there is no treatment able to cure the disease, it is important to come back to basic research and to explore new ways of research and treatment such as those explored by Viral Genetics. This is why I joined the Advisory Board of this Company.”

This is a certain break in the log-jam of political posturing about Lyme disease.  Already Viral Genetics, the biotechnology company that discovers and develops immune-based therapies, came upon particular simularities in the testing of HIV that allowed them to look at Lyme disease in a whole new way.  It has been generally agreed upon that there needs to be agreement based on exact science not theories.

The purpose of the Viral Genetics Advisors is to provide independent wisdom and insight to assist Viral Genetics in the accomplishment of its medical and scientific objectives by providing advice that is consistent with best-in-class scientific and medical practices and principles.

Based on new information from ongoing AIDS and Lyme disease studies being led by head of research Dr. M. Karen Newell, PhD, new components of the mechanism of TNP, the Company’s drug compound, have been identified according to the Wall Street Journal.

Viral Genetics continues to aggressively seek out the appropriate individuals in relevant fields to assist as the studies continue to move forward. These will include highly sought-after individuals in many diverse fields of research.

The existing group and new advisers to be added have come together in an effort to spearhead Viral Genetics’ promising new model of targeted peptide therapies for AIDS and other immune disease as swiftly as possible.

This may be the best Holiday present we could have